Anti-helicobacter pylori effect of total alkaloids of sophora alopecuroides in vivo

被引:11
|
作者
Tian Aiping [1 ]
Xu Ting [1 ]
Liu Kaiyun [2 ]
Zou Quanming [2 ]
Yan Xiang [3 ]
机构
[1] Lanzhou Univ, Clin Med Sch 1, Lanzhou 730000, Gansu, Peoples R China
[2] Third Mil Med Univ, Dept Clin Microbiol, Chongqing 400000, Peoples R China
[3] Lanzhou Univ, Hosp 1, Dept Gerontol, Lanzhou 730000, Gansu, Peoples R China
关键词
total alkaloid of Sophora alopecuroides; Helicobacter pylori; cyclooxygenase; 2; nuclear factor-kappa B; interleukin; 8; GASTRIC EPITHELIAL-CELLS; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; ACID PHENETHYL ESTER; INDUCED EXPRESSION; CYCLOOXYGENASE; AGS CELLS; INFECTION; MANAGEMENT; MICE;
D O I
10.3760/cma.j.issn.0366-6999.20140615
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Helicobacter pylori (H. pylon) infection could lead to most gastroduodenal diseases and is even identified as a carcinogen of gastric cancer. Total alkaloids of sophora alopecuroides (TASA) is widely used in herbal remedies to treat various infectious diseases, including stomach-associated diseases. This study is aimed at evaluating the antimicrobial activity of TASA on H. pylori-infected BALB/c mice mouse gastritis. Methods Totally 120 BALB/c mice were orally inoculated with H. pylori Bacterial liquid to construct BALB/c mice H. pylori infection gastritis animal model, after the model was successfully created. We randomly assigned 100 infected mice into 10 treatment groups, the first group (normal saline); the second group (bismuth pectin); the third group (omeprazole); the fourth group (TASA 2 mg/d); the fifth group (TASA 4 mg/d); the sixth group (TASA 5 mg/d); the seventh group (TASA + bismuth pectin); the eighth group (TASA + omeprazole); the ninth group (bismuth pectin + clarithromycin + metronidazole); the tenth group (omeprazole + clarithromycin + metronidazole), 5 other non-infected mice as negative control. Mice were orally inoculated twice a day and 7 days continuously. Then the mice were killed 4 weeks after treatment, we used real-time PCR to detect 16sDNA of H. pylon to test both the colonization and the clearance mice of bacteria of each treatment. We applied hematoxylin and eosin (HE) staining and immunostaining of mice gastric mucosa to observe the general inflammation and related factors interleukin 8 (IL-8), cyclooxygenase 2 (COX-2), and nuclear factor-kappa B (NF-kappa B) expression change after treatments. Results Firstly, we ensured that after 6-week intragastric administration, the bacteria colonization reached an exceed peak which is far higher than positive threshold (P <0.001); secondly, after treatments, it is revealed that TASA combined with omeprazole or bismuth pectin showed promising antimicrobial activity against H. pylori as well as conventional triple therapy (P <0.001); thirdly, HE staining showed that the inflammation on mice gastric mucosal membrane were also relieved obviously in TASA combined treatments and conventional triple therapy compared with normal saline treated mice, moreover, from immunohistochemistry results, H. pylon-induced IL-8, COX-2, and NF-kappa B were consistently suppressed in seventh, eighth, ninth, and tenth group to a certain extent. Conclusion These results open the possibility of taking TASA as an anti-inflammatory agent for H. pylori gastritis.
引用
收藏
页码:2484 / 2491
页数:8
相关论文
共 50 条
  • [1] Anti-Helicobacter pylori activities of Chenopodium ambrosioides L. in vitro and in vivo
    Ye, Hui
    Liu, Yu
    Li, Ning
    Yu, Jing
    Cheng, Hong
    Li, Jiang
    Zhang, Xue-Zhi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (14) : 4178 - 4183
  • [2] ANTI-HELICOBACTER PYLORI VACCINE: MITH OR REALITY?
    Uspenskiy, Yu. P.
    Baryshnikova, N., V
    Ermolenko, E., I
    Suvorov, A. N.
    Svarval, A., V
    INFEKTSIYA I IMMUNITET, 2019, 9 (3-4): : 457 - 466
  • [3] Anti-Helicobacter pylori activity of Terminalia macroptera root
    Silva, Olga
    Viegas, Silvia
    de Mello-Sampayo, Cristina
    Costa, Maria Joao P.
    Serrano, Rita
    Cabrita, Jose
    Gomes, Elsa T.
    FITOTERAPIA, 2012, 83 (05) : 872 - 876
  • [4] Anti-Helicobacter pylori activity of quinolone alkaloids from evodiae fructus
    Rho, TC
    Bae, EA
    Kim, DH
    Oh, WK
    Kim, BY
    Ahn, JS
    Lee, HS
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1999, 22 (10) : 1141 - 1143
  • [5] In vitro anti-Helicobacter pylori activity of ebrotidine
    Palacin, C
    Tarrago, C
    Sacristan, A
    Ortiz, JA
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1997, 47-1 (4A): : 471 - 474
  • [6] Daphnetin: A Novel Anti-Helicobacter pylori Agent
    Wang, Genzhu
    Pang, Jing
    Hu, Xinxin
    Nie, Tongying
    Lu, Xi
    Li, Xue
    Wang, Xiukun
    Lu, Yun
    Yang, Xinyi
    Jiang, Jiandong
    Li, Congran
    Xiong, Yan Q.
    You, Xuefu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (04):
  • [7] In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives
    Sposito, Larissa
    Oda, Fernando Bombarda
    Vieira, Julia Hunger
    Carvalho, Flavio Alexandre
    dos Santos Ramos, Matheus Aparecido
    de Castro, Rogerio Cardoso
    Crevelin, Eduardo Jose
    Miller Crotti, Antonio Eduardo
    Santos, Andre Gonzaga
    da Silva, Patricia Bento
    Chorilli, Marlus
    Bauab, Tais Maria
    JOURNAL OF ETHNOPHARMACOLOGY, 2019, 233 : 1 - 12
  • [8] The Controversy over Anti-Helicobacter pylori Therapy
    Bocian, Katarzyna M.
    Jagusztyn-Krynicka, Elzbieta K.
    POLISH JOURNAL OF MICROBIOLOGY, 2012, 61 (04) : 239 - 246
  • [9] Anti-Helicobacter pylori IgG titre in patients with chronic idiopathic urticaria and the effect of Helicobacter pylori eradication on urticaria
    Kolacinska-Flont, Marta
    Antczak-Marczak, Monika
    Pawlowski, Maciej
    Kuna, Piotr
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2012, 29 (02): : 80 - 85
  • [10] Anti-Helicobacter pylori activity of ethoxzolamide
    Modak, Joyanta K.
    Tikhomirova, Alexandra
    Gorrell, Rebecca J.
    Rahman, Mohammad M.
    Kotsanas, Despina
    Korman, Tony M.
    Garcia-Bustos, Jose
    Kwok, Terry
    Ferrero, Richard L.
    Supuran, Claudiu T.
    Roujeinikova, Anna
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 1660 - 1667